Baby Beat represents our innovative response to the declining birthrate, increasing pregnancy risks and risks related to the generally higher age of pregnant women. It consists of a bracelet with integrated non-invasive technology that continuously measures the fetal heartbeat 24 hours, 7 days a week from around Week 20 of the pregnancy. This wearable device communicates with smart phones via Bluetooth and generates automatic alarms when the fetal heartbeat exceeds specific thresholds. The main innovations are that this method is non-invasive unlike all other devices available on the market and that it will be available at an attainable price of a few hundred euros. The overall objective of Phase II is to miniaturize the existing prototype, to test and demonstrate its usefulness on a larger group of pregnant women in clinical trials, and to obtain the necessary certifications for Baby Beat to become a medical device. The market size for Baby Beat is promising when considering the number of pregnancies per year, following the trends of the prenatal retail market and considering the boom of non-invasive prenatal tests. There are 23 million pregnancies in the developed world itself. We will follow a two-tiered business model with direct sales through pharmacies and indirect sales through insurance companies, hospitals and clinics. This will allow us to boost our company growth and to create a significant amount of new jobs. With our medical device and software, we foster the prevention of prenatal problems, and facilitate the provision of personalized care: high risk cases do not remain undiscovered, risk patients only proceed with visits if Baby Beat indicates a need, risk patients do not need to be hospitalized and different agents of the healthcare system will better coordinated.

The Vision of HypoSens is to develop a widely accepted,non-invasive and crucial prognostic tool for breast cancer progression in early stages to help clinicians and specially oncologists to decide about prompt therapy approaches to patients and improve quality of life and expectancy. Our breakthrough research will focus on the development, pre-clinical and clinical validation, and industrial demonstration of a unique all optical cancer prognostic system that will determine presence of cancer cells in the breast lymph nodes and characterize them, which correlates with presence of metastasis and bad prognosis. HypoSens prognostic system will consist of a non-invasive Near-infrared imaging device able to register signals through scattering media enabled by the implementation of wavefront shaping,that will process data collected by injected tumour-targeted body antibody functionalised nano-particles containing porphyrin sensors that will determine local oxygen concentration and local temperature distribution in the cancer cells.The HypoSens imaging system is strategically designed to offer a non-invasive alternative to the Sentinel Lymph Node Biopsy,the current surgical procedure for breast cancer staging. With an approximate cost of 60,000€ per device unit and additional 5,000€ per patient, the device is an affordable, accurate, easy to use prognostic solution for clinicians towards more accurate and fast diagnostics and personalised treatment options.The initial target of the project is metastatic breast cancer, with potential later involvement in other cancer markets, e.g. vulval, renal, colorectal, gastric etc (via the use of different tumor-targeting moiety).With an estimated 1.7 million new cases each year, breast cancer is the most common cancer among women worldwide.Its low cost will enable a wide and fast take-up by clinicians and hospitals leading to an important reduction of the economic and societal burden related to the diagnosis and treatment of cancer.

VIZTA project, coordinated by ST Micrelectronics, aims at developing innovative technologies in the field of optical sensors and laser sources for short to long-range 3D-imaging and to demonstrate their value in several key applications including automotive, security, smart buildings, mobile robotics for smart cities, and industry4.0. The key differentiating 12-inch Silicon sensing technologies developed during VIZTA are: • Innovative SPAD and lock-in pixel for Time of Flight architecture sensors • Unprecedent and cost-effective NIR and RGB-Z filters on-chip solutions • complex RGB+Z pixel architectures for multimodal 2D/3D imaging For short-range sensors : advanced VCSEL sources including wafer-level GaAs optics and associated high speed driver These developed differentiating technologies allows the development and validation of innovative 3D imaging sensors products with the following highly integrated prototypes demonstrators: • High resolution (>77 000 points) time-of-flight ranging sensor module with integrated VCSEL, drivers, filters and optics. • Very High resolution (VGA min) depth camera sensor with integrated filters and optics For Medium and Long range sensing, VIZTA also adresses new LiDAR systems with dedicated sources, optics and sensors Technology developments of sensors and emitters are carried out by leading semiconductor product suppliers (ST Microelectronics, Philips, III-V Lab) with the support of equipment suppliers (Amat, Semilab) and CEA Leti RTO. VIZTA project also include the developement of 6 demonstrators for key applications including automotive, security, smart buildings, mobile robotics for smart cities, and industry4.0 with a good mix of industrial and academic partners (Ibeo, Veoneer, Ficosa, Beamagine, IEE, DFKI, UPC, Idemia, CEA-List, ISD, BCB, IDE, Eurecat). VIZTA consortium brings together 23 partners from 9 countries in Europe: France, Germany, Spain, Greece, Luxembourg, Latvia, Sweden, Hungary, and United Kingdom.